Syverson Strege & Co’s AbbVie ABBV Stock Holding History

Syverson Strege & Co’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.48M	Sell	5,870 -616	-9%	-$133K	0.32%	36
2026 Q1	$1.41M	Sell	6,486 -88	-1%	-$19.5K	0.34%	34
2025 Q4	$1.5M	Buy	6,574 +76	+1%	+$17.3K	0.36%	32
2025 Q3	$1.5M	Buy	6,498 +492	+8%	+$100K	0.36%	31
2025 Q2	$1.11M	Buy	6,006 +1,414	+31%	+$263K	0.26%	44
2025 Q1	$962K	Buy	4,592 +38	+0.8%	+$7.39K	0.31%	31
2024 Q4	$809K	Buy	4,554 +1,304	+40%	+$240K	0.27%	32
2024 Q3	$642K	Sell	3,250 -806	-20%	-$150K	0.22%	36
2024 Q2	$696K	Buy	+4,056	New	+$672K	0.24%	35
2022 Q3	–	Sell	-75	Closed	-$11K	–	281
2022 Q2	$11K	Buy	+75	New	+$11.5K	﹤0.01%	215
2022 Q1	–	Sell	-20	Closed	-$3K	–	297
2021 Q4	$3K	Sell	20 -9	-31%	-$1.06K	﹤0.01%	251
2021 Q3	$3K	Buy	+29	New	+$3.31K	﹤0.01%	360

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Syverson Strege & Co's ABBV Position: Q2 2026 in Review

Syverson Strege & Co reduced its AbbVie (ABBV) stake by 9.5% in Q2 2026, selling an estimated $133K and leaving 5,870 shares worth $1.48M. The position accounts for 0.32% of the portfolio, ranked #36.

Syverson Strege & Co first reported a position in ABBV in Q3 2021 and has held it in 12 quarters since. The position peaked at $1.5M in Q3 2025. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Syverson Strege & Co held 5,870 shares of AbbVie worth $1.48M as of Q2 2026.
Syverson Strege & Co sold 616 AbbVie shares in Q2 2026, an estimated $133K.
AbbVie made up 0.32% of Syverson Strege & Co's portfolio in Q2 2026, its #36 holding.
Syverson Strege & Co first reported a position in AbbVie in Q3 2021 and has held it in 12 quarters since.
Syverson Strege & Co's AbbVie position peaked at $1.5M in Q3 2025.
4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Syverson Strege & Co's 13F filing for Q2 2026, filed 6 Aug 2026.